Article Text

Download PDFPDF

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma
  1. Miya Hugaboom1,
  2. Kelly Street2,
  3. Neil Ruthen3,
  4. Lena Wirth1,
  5. Opeyemi A Jegede3,
  6. Nicholas Schindler1,
  7. David F McDermott4,
  8. Elizabeth Plimack5,
  9. Jeffrey Sosman6,
  10. Naomi B Haas7,
  11. Michael Hurwitz1,
  12. Hans Hammers8,
  13. Sabina Signoretti9,
  14. Michael B Atkins10,
  15. Catherine J Wu3 and
  16. David Braun4
  1. 1Yale School of Medicine, New Haven, CT, USA
  2. 2Keck School of Medicine of USC, Los Angeles, CA, USA
  3. 3Dana-Farber Cancer Institute, Boston, MA, USA
  4. 4Beth Israel Deaconess Medical Center, Boston, MA, USA
  5. 5Fox Chase Cancer Center, Philadelphia, PA, USA
  6. 6Northwestern University, Chicago, IL, USA
  7. 7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
  8. 8UT Southwestern, Coppell, TX, USA
  9. 9Brigham and Women’s Hospital, Boston, MA, USA
  10. 10Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Renal cell carcinoma (RCC) is an immunologically paradoxical tumor. Despite high T cell infiltration, increased CD8+ T cells are not associated with response to programmed cell death 1 (PD-1) blockade.1 Through single-cell transcriptomic analysis, we previously identified a population of SLAMF7+ CD8+ exhausted T cells that was associated with resistance to nivolumab monotherapy in the HCRN GU16–260 trial (NCT03117309) (Braun, ASCO, 2023). In the present study, we generated a gene expression signature (GES) to capture the proportion of this SLAMF7+ T cell population and investigated the association of this GES with clinical outcomes in an external RCC cohort, CheckMate-025.1

Methods For each gene in our bulk RNA sequencing (RNA-seq) expression matrix, we determined the Spearman correlation between the gene’s normalized expression level and the proportion of SLAMF7+ CD8+ T cells in patients with matched single cell (scRNA-seq) and bulk RNA-seq data (n = 7). Following z-scoring of all genes, we calculated the average expression of the twenty genes with the highest Spearman correlation coefficient to generate a GES score for all samples without matched scRNA-seq data in the HCRN GU16–260 cohort (n = 85). Both correlation and GES scoring included samples of clear cell and non-clear cell histology. GES scoring was repeated separately for patients receiving anti-PD1 monotherapy (nivolumab; n = 172) or mTOR inhibitor (everolimus; n = 109) monotherapy in the CheckMate-025 cohort.

Results Patients with progressive disease (PD) had higher GES scores than those with complete/partial response (CR/PR) in both HCRN GU16–260 (p=0.027) and the nivolumab arm of the CheckMate-025 (p=0.0058) cohort. Similarly, high ( ≥ median) scores were associated with worse progression free survival (PFS) (HCRN p=0.045, HR [95% CI] =1.72 [1.02–2.9]; CheckMate-025 nivolumab p=0.03, HR [95% CI] =1.62 [1.07–2.46]) in these cohorts. The same patterns were observed in clear cell and non-clear cell subsets of the HCRN GU16–260 cohort. Conversely, for the everolimus arm of CheckMate-025, there were no differences in scores between PD and CR/PR groups (p=0.4) or association with PFS (p=0.81, HR [95% CI] = 1.06 [0.65–1.74]).

Conclusions We present a GES characteristic of SLAMF7+ CD8+ exhausted T cells that is associated with worse clinical outcomes in patients receiving anti-PD1 monotherapy, but not in patients receiving mTOR inhibitor monotherapy. Future work will aim to validate our findings in additional external RCC cohorts, examine the applicability of our findings to additional cancer types, and experimentally interrogate the impact of SLAMF7 signaling on CD8+ T cell function.


  1. Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26:909–918.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.